Accelerate test internalization with PGDx elio™ plasma focus Dx, an FDA-authorized liquid biopsy-based genomic profiling solution

Liquid biopsy next-generation sequencing (NGS) assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable or during disease progression. Extensive analytical validation of the targeted 33-gene assay, PGDx elio plasma focus Dx, has shown that detection of cancer-associated variants in circulating tumor DNA (ctDNA) is highly specific, sensitive, reproducible and accurate. Distribution of this kitted assay, including automated machine-learning software to generate reports, can inform precision oncology decision-making.

 

Learning Objectives